Drug therapy for double-hit lymphoma
Double-hit lymphoma (DHL) is a rare type of aggressive B-cell lymphoma defined as a high-grade B-cell lymphoma (HGBCL) with the presence of MYC, BCL2 and/or BCL6 rearrangements. Patients usually present with rapidly progressive and advanced stage of disease and, commonly, with extranodal involvement...
Main Authors: | Vania Phuoc, Jose Sandoval-Sus, Julio C Chavez |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2019-12-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/drug-therapy-for-double-hit-lymphoma/ |
Similar Items
-
Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma
by: Yuanhui Liu, et al.
Published: (2019-11-01) -
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
by: Weiping Li, et al.
Published: (2019-07-01) -
Double-Hit and Triple-Hit Lymphomas: New Perspectives for Their Classification
by: Cristiano Claudino Oliveira, et al.
Published: (2017-08-01) -
Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience
by: Tingting Zhang, et al.
Published: (2021-09-01) -
Clinical features and therapy of double-hit and double-expressor lymphomas
by: E A Baryakh, et al.
Published: (2016-12-01)